- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01034007
A Pilot Study Investigating the Clinical Use of Tissue Engineered Vascular Grafts in Congenital Heart Surgery
February 28, 2018 updated by: Christopher Breuer
An initial feasibility and safety study evaluating the use of autologous tissue engineered vascular grafts as extra cardiac total cavopulmonary connection (EC TCPC) conduits in children with single ventricle anomalies.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This investigation is a prospective, nonrandomized phase 1 clinical trial determining the safety of the use of tissue engineered vascular grafts as conduits for EC TCPC.
Primary end points of the study will include determination of graft failure rates and graft related morbidity and mortality.
Graft failure will be defined as any graft narrowing/occlusion or dilation/rupture requiring surgical or endovascular intervention.
Graft related morbidity and mortality will include any post-operative complication such as any thromboembolic or infectious event that requires treatment and is thought likely to be caused by the tissue engineered vascular graft as determined by the investigators and confirmed by the data safety monitoring board.
All appropriate patients requiring EC TCPC who meet study inclusion/exclusion criteria will be evaluated for enrollment in the clinical trial.
After obtaining informed consent from the patient's parents, patients with single ventricle cardiac anomalies will undergo EC TCPC using a tissue engineered conduit.
Post-operative care and monitoring will follow an established, standardized, clinical algorithm in which the patient's clinical status including complications and measurements of graft function will be serially evaluated and recorded over a three year period using physical examination, echocardiography, and MRA.
Study Type
Interventional
Enrollment (Actual)
4
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43205
- Nationwide Children's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 100 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- single ventricle cardiac anomaly requiring extra cardiac total cavopulmonary connection (EC TCPC).
Exclusion Criteria:
- incomplete inferior vena cava (IVC)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tissue Engineered Vascular Grafts
|
Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance angiography (MRA)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
graft failure requiring intervention
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
graft growth
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mark Galantowicz, MD, Nationwide Children's Hospital
- Study Chair: Christopher K Breuer, MD, Nationwide Children's Hospital, Columbus, Ohio
- Study Chair: Toshiharu Shinoka, MD/PhD, Nationwide Children's Hospital, Columbus, Ohio
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2009
Primary Completion (Actual)
December 26, 2017
Study Completion (Actual)
January 23, 2018
Study Registration Dates
First Submitted
January 29, 2008
First Submitted That Met QC Criteria
December 15, 2009
First Posted (Estimate)
December 17, 2009
Study Record Updates
Last Update Posted (Actual)
March 2, 2018
Last Update Submitted That Met QC Criteria
February 28, 2018
Last Verified
February 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCHIRB12-00357
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Single Ventricle Cardiac Anomaly
-
Timothy Icenogle, MDWithdrawnSingle-ventricle | Failing Fontan Physiology | Failing Fontan | Single-ventricle Fontan | Single-ventricle PhysiologyUnited States
-
Barbara BurkhardtNot yet recruitingSingle-ventricleSwitzerland
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); The Methodist Hospital Research...Recruiting
-
HealthCore-NERINational Heart, Lung, and Blood Institute (NHLBI)CompletedSingle Ventricle PhysiologyUnited States
-
University of MichiganTerminated
-
Hacettepe UniversityCompleted
-
Washington University School of MedicineCompletedSingle Ventricle Fontan PalliationUnited States
-
Emory UniversityTerminatedAmbulatory Children With Single VentricleUnited States
-
Stanford UniversityVanderbilt University Medical Center; Adult Congenital Heart Association; Julie... and other collaboratorsNot yet recruitingSingle-ventricle | Heart Failure CongenitalUnited States
-
Mezzion Pharma Co. LtdRecruitingSingle Ventricle Heart DiseaseUnited States
Clinical Trials on Tissue Engineered Vascular Grafts
-
Nationwide Children's HospitalNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsRecruitingHeart Diseases | Cardiovascular Diseases | Heart Defects, Congenital | Cardiovascular Abnormalities | HLH - Hypoplastic Left Heart Syndrome | DORV | DILV - Double Inlet Left Ventricle | Mitral Atresia | Tricuspid Atresia | Unbalanced AV Canal | Single-ventricleUnited States
-
First Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
A.A. Partners, LLCUnknown
-
Vascutek Ltd.Terminated
-
University College, LondonMedical Research CouncilWithdrawnTracheal Stenosis | Laryngostenosis | Disorder of Upper Respiratory SystemUnited Kingdom
-
W.L.Gore & AssociatesRecruitingEnd-Stage Renal Disease | AAA - Abdominal Aortic Aneurysm | PAD - Peripheral Arterial DiseaseSpain, Italy, France
-
Institut National de la Santé Et de la Recherche...Active, not recruitingEpidermolysis Bullosa Dystrophica, RecessiveFrance
-
Wake Forest University Health SciencesUnited States Department of DefenseNot yet recruitingUrologic Diseases | Trauma Injury | Penile Diseases | Male Urogenital Diseases | Corpus Callosum Malformation | Corpora Cavernosa; InflammationUnited States
-
University Hospital, Basel, SwitzerlandDeutsche Arthrose-HilfeCompletedDegenerative Lesion of Articular Cartilage of Knee | Cartilage LesionSwitzerland
-
Amarantus BioScience Holdings, Inc.Amarex Clinical ResearchUnknownThermal Injury | Deep Partial-Thickness Burn | Full-Thickness BurnUnited States